I just wonder can i take like 1 gramm dried golden teacher or like 2.5 gramm atlantis truffels just to get into the psychedelic headspace, meditatng somehwat listen to psychedelic musik and enjoy myself?

Maybe some nice visuals. Is that possible? Or are psychedelics always hard to digest, no matter how low the dose?

Well, the thing is that shrooms have a difficult personality.

The only situation I would do lower doses of psyches is when I feel bored to be somewhere, and than take just enough to make it more interesting in my head

What you are experiencing (during a "psychedelic" experience) is always yourself, it is all (from) you. Psychs are just one stimuli out of infinte which can trigger the upcoming of a certain topic. It is not about the topic itself but the way to deal (coping) with it.

I personally love low doses...so versatile. But to each their own

all doses are amazin.

Experimental evidence of psychedelic cognitive enhancement comes from studies of practical problem solving, abstract concepts, and psychotherapy.

A significant instance of problem solving resulted in a Nobel Prize for Kary Mullis. Until the invention of the polymerase chain reaction (PCR), a common problem in biology was that biological samples were often too small to analyze, but Mullis solved that and won a Nobel Prize. He described how LSD aided him in doing so.

"PCR's another place where I was down there with the molecules when I discovered it and I wasn't stoned on LSD, but my mind by then had learned how to get down there. I could sit on a DNA molecule and watch the [indistinct] go by. . . . I've learned that partially I would think, and this is again my opinion, through psychedelic drugs . . . if I had not taken LSD ever would I have still been in PCR? I don't know, I doubt it, I seriously doubt it." (Mullis 1998; "Horizon: Psychedelic Science" 1997)

From the point of view of psychedelic cognitive studies, Mullis's example is noteworthy because he did not have his insight while taking psychedelics but instead used psychedelics to increase his ability to visualize, then transferred that cognitive skill back to his ordinary mindbody state. This confirms the idea that some skills learned in one state can be transferred to another. Transference and nontransference between mindbody states is itself a cognitive process that deserves study — learning to remember dreams, for example. Learning to increase this flow, if it is possible, would increase access to stores of information and possibly to new cognitive skills.

Unlike Mullis's experience of transferring a skill back to his ordinary state, most instances of psychedelic problem solving occur while the person's cognitive processes are psychedelically augmented. This is most clearly illustrated by "Psychedelic Agents in Creative Problem Solving: A Pilot Study," by Willis Harman, a professor of engineering economic systems, and a team of researchers at Stanford Research Institute. Working with twenty-seven men who were "engaged in various professional occupations, i.e., engineers, physicists, mathematicians, architects, a furniture designer, and a commercial artist and had a total of 44 professional problems they wanted to work on," the Stanford Research Institute team divided them into groups of three or four and gave them 200 milligrams of mescaline, followed by a quiet period of listening to music. Then they had snacks and discussed their problems with their group. Following this they spent three or four hours working alone on their problems. As a result of psychedelic enhancement, the practical results were impressive.
http://realitysandwich.c...nding_cognitive_studies/

Tania: Switching gears to the Iodo compounds, like DOI, did you mention that these are anti-inflammatory?

Dave: Yeah, that's very weird.

Tania: Some guy called in to Sasha's office, saying that he had rheumatoid arthritis, and he took 2C-I, and for two weeks he was pain-free. Which makes me wonder about medical applications for the Iodo compounds...

Dave: My son Chuck discovered that accidentally. He's an associate professor at Louisiana State University in New Orleans. He wanted to work with 5-HT2 agonists, because he's looking at serotonin receptors in Drosophila, and doing translational stuff into rats. He asked, "Is there a 5-HT2A agonist that's not a controlled substance that I can use?" Since DOI was not controlled, I sent him the isomers of DOI.

His team had been using rat aortic epithelial cells--cells from the inside of a rat's blood vessels--and looking at models of atherosclerosis. The model they'd been using was to take these cells, and put in TNF-alpha (tumor necrosis factor-alpha), a pro-inflammatory substance. If you've seen the advertisements for Enbrel, for arthritis, drugs such as that block TNF-alpha receptors, so they block the pain. What they would do is put TNF-alpha directly into these cells and then they would look at what effect occurred in combination with other compounds--there were four or five compounds that they were looking at.

So his post-doc had some of those cells that were grown up and could be used, and he asked my son, "What if I run a test with one of our compounds in these?" And Chuck said, "Well, I don't have any anti-inflammatory compounds right now." "What about this DOI here?" Chuck laughed and replied, "That's a hallucinogen. That won't do anything." The post-doc said, "Well, I'm going to have to destroy the cells. Can I just go ahead and test it?" And Chuck said, "Yeah, go ahead." The guy came back a week and a half later and said, "The DOI completely blocked TNF-alpha at 20 picomolar." Which is like unbelievable, right?

Chuck said, "Nah. You made a mistake." So Chuck went in, made up his own fresh solutions, took the cells, ran the experiment, and reproduced the guy's data. He wrote me back and asked, "Is there any precedent for this?" And I said, "No, not that I know of." So he published a paper in J PET; it was the featured paper in the issue it was published in. This has extraordinary potency; there's no anti-inflammatory that has potency like that.
https://www.erowid.org/c...s_david_interview1.shtml

Tumor necrosis factor alpha (TNF-α) plays a key role in inflammation, and its production and signaling contribute to many inflammatory related diseases. Recently, we discovered that selective activation of serotonin 5-HT2A receptors with the agonist (R)-DOI produces a super-potent blockade of proinflammatory markers in primary rat aortic smooth muscle cells. Here, we demonstrate that systemic administration of (R)-DOI can block the systemic effects of TNF-α in whole animal, with potent anti-inflammatory effects in the aortic arch and small intestine. This includes blockade of TNF-α-induced expression of pro-inflammatory cell adhesion (Icam-1, Vcam-1), cytokine (Il-6, IL-1b), and chemokine (Mcp-1, Cx3cl1) genes, and expression of VCAM-1 protein in the intestine. Further, systemic (R)-DOI also prevents the TNF-α-induced increase of circulating IL-6. Importantly, utilizing receptor selective antagonists, we have demonstrated that the mechanism underlying the systemic anti-inflammatory effects of (R)-DOI is activation of serotonin 5-HT2A receptors. Our results highlight a powerful new role for the serotonin 5-HT2A receptor in inflammatory processes, and indicate that agonism of serotonin receptors may represent an effective and novel approach to develop powerful small molecule therapeutics for inflammatory diseases and conditions such as atherosclerosis and inflammatory bowel disease. http://journals.plos.org...371/journal.pone.0075426

Psychedelic drug prevents asthma development in mice
Date:February 9, 2015
Source: Louisiana State University Health Sciences Center
Summary:
Researchers have found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model. The effects are potent and effective at a concentration 50-100 times less than would influence behavior.

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model. The effects are potent and effective at a concentration 50-100 times less than would influence behavior. The research was published in the January 15 issue of the American Journal of Physiology -- Lung Cellular and Molecular Physiology.
https://www.sciencedaily...2015/02/150209171311.htm